Back to results
US 12,740,989 B2Granted
Notch signaling inhibitors for treating obesity and metabolic disorders
AssigneePurdue Research Foundation
InventorsMeng Deng, Di Huang, Shihuan Kuang
Life of this patent
Estimating the term…
Abstract
Provided is the use of Notch signaling inhibitors such as γ-secretase inhibitors (GSIs), which increase expression of uncoupling protein-1 (UCP-1), to selectively increase browning of white adipose tissue, for example, in the treatment of obesity and metabolic disorders such as type 2 diabetes mellitus (T2DM), fatty liver disease, atherosclerosis, and others, including comorbidities thereof.
Claims18
A γ-secretase inhibitor (GSI), or a derivative, prodrug, or pharmaceutically acceptable salt thereof, which increases expression of uncoupling protein-1 (UCP-1), having the structure shown below:
- including pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates, and diastereomeric mixtures thereof.
Dependencies are inferred from the claim text.